KRAS and sarcoma: In the STS cohort, KRAS G12C mutations were identified angiosarcoma (n=2), sarcoma NOS (n=2), myxoid/round-cell liposarcoma (n=1), and undifferentiated pleomorphic sarcoma (n=1).